Rosiglitazone is a potent and selective PPARγ agonist (EC50 = 60 nM); exhibits no activity at PPARα and PPARβ. Promotes differentiation of pluripotent C3H10T1/2 stem cells into adipocytes. Also promotes differentiation of urothelial organoids in combination with erlotinib. Ameliorates endotoxin-induced organ damage in conscious rats.
